Skip to main content
. 2015 May 1;17(4):976–987. doi: 10.1208/s12248-015-9762-4

Fig. 6.

Fig. 6

ab Effect of PDL-1, PDL-2, and nivolumab on QC sample performance. a sPD-1 in a melanoma serum sample measured in the absence or presence of 20 nM (1 μg/mL) of human PDL-1 or PDL-2 proteins. b QC performance from analytical runs in the absence or presence of 685 nM (100 μg/mL) nivolumab. Results are shown as mean and SD of each group (n = 2–4)